What is the recommended follow-up for patients with monoclonal gammopathy of undetermined significance (MGUS) at risk for malignant progression?

Updated: Sep 07, 2018
  • Author: Suzanne R Fanning, DO; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

With IgM MGUS, which poses a high risk for malignant progression, some experts recommend more intensive follow-up, with twice-annual visits that include clinical assessment, CBC, comprehensive metabolic panel, serum protein electrophoresis, serum FLC assay, and quantitative immunoglobulin serum electrophoresis. [37]

The European Myeloma Network advises that for low-risk MGUS, follow-up at 6 months and every 1–2 years thereafter can be justified. Alternatively, follow-up for low-risk MGUS may be limited to performing laboratory studies or bone marrow analysis when patients develop symptoms suggestive of MM or related diseases. In patients who are elderly or have significant morbidity with a short life expectancy, it may be reasonable to forgo follow-up. [3]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!